456 related articles for article (PubMed ID: 26307625)
41. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies.
Robert C; Soria JC; Eggermont AM
Eur J Cancer; 2013 Sep; 49(14):2968-71. PubMed ID: 23907003
[TBL] [Abstract][Full Text] [Related]
42. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.
Swaika A; Hammond WA; Joseph RW
Mol Immunol; 2015 Oct; 67(2 Pt A):4-17. PubMed ID: 25749122
[TBL] [Abstract][Full Text] [Related]
43. PD-L1 detection using
Vento J; Mulgaonkar A; Woolford L; Nham K; Christie A; Bagrodia A; de Leon AD; Hannan R; Bowman I; McKay RM; Kapur P; Hao G; Sun X; Brugarolas J
J Immunother Cancer; 2019 Jun; 7(1):144. PubMed ID: 31155004
[TBL] [Abstract][Full Text] [Related]
44. PD-1-targeted immunotherapy: recent clinical findings.
Brahmer JR
Clin Adv Hematol Oncol; 2012 Oct; 10(10):674-5. PubMed ID: 23187774
[No Abstract] [Full Text] [Related]
45. The PD-1/PD-L1 axis may be aberrantly activated in occupational cholangiocarcinoma.
Sato Y; Kinoshita M; Takemura S; Tanaka S; Hamano G; Nakamori S; Fujikawa M; Sugawara Y; Yamamoto T; Arimoto A; Yamamura M; Sasaki M; Harada K; Nakanuma Y; Kubo S
Pathol Int; 2017 Mar; 67(3):163-170. PubMed ID: 28139862
[TBL] [Abstract][Full Text] [Related]
46. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
[TBL] [Abstract][Full Text] [Related]
47. Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report.
Noguchi G; Tsutsumi S; Yasui M; Ohtake S; Umemoto S; Nakaigawa N; Yao M; Kishida T
BMC Urol; 2018 Apr; 18(1):26. PubMed ID: 29669553
[TBL] [Abstract][Full Text] [Related]
48. PD-1 blockade in renal cell carcinoma: to equilibrium and beyond.
Harshman LC; Drake CG; Choueiri TK
Cancer Immunol Res; 2014 Dec; 2(12):1132-41. PubMed ID: 25480555
[TBL] [Abstract][Full Text] [Related]
49. A novel prognostic model for patients with sarcomatoid renal cell carcinoma.
Zhang BY; Thompson RH; Lohse CM; Leibovich BC; Boorjian SA; Cheville JC; Costello BA
BJU Int; 2015 Mar; 115(3):405-11. PubMed ID: 24730416
[TBL] [Abstract][Full Text] [Related]
50. Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy.
Diamond E; Molina AM; Carbonaro M; Akhtar NH; Giannakakou P; Tagawa ST; Nanus DM
Crit Rev Oncol Hematol; 2015 Dec; 96(3):518-26. PubMed ID: 26321263
[TBL] [Abstract][Full Text] [Related]
51. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
52. PD-1/PD-L1 inhibitors.
Sunshine J; Taube JM
Curr Opin Pharmacol; 2015 Aug; 23():32-8. PubMed ID: 26047524
[TBL] [Abstract][Full Text] [Related]
53. Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
Beuselinck B; Lerut E; Wolter P; Dumez H; Berkers J; Van Poppel H; Joniau S; Oyen R; De Wever L; Strijbos M; Paridaens R; Schöffski P
Clin Genitourin Cancer; 2014 Oct; 12(5):e205-14. PubMed ID: 24861951
[TBL] [Abstract][Full Text] [Related]
54. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.
Paydas S; Bağır E; Seydaoglu G; Ercolak V; Ergin M
Ann Hematol; 2015 Sep; 94(9):1545-52. PubMed ID: 26004934
[TBL] [Abstract][Full Text] [Related]
55. A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity.
Luan Y; Chai D; Peng J; Ma S; Wang M; Ma H; Li X; Fu S; Pan X; Wang X; Qin S; Xu T
Int Immunopharmacol; 2016 Feb; 31():248-56. PubMed ID: 26773772
[TBL] [Abstract][Full Text] [Related]
56. Outcomes of Patients With Advanced Renal Cell Carcinoma With Non-Clear Cell Histology Treated With Systemic Therapy.
Urman D; Deshler L; Weise N; Shabaik A; Derweesh I; Bagrodia A; Rose B; Herchenhorn D; McKay RR
Clin Genitourin Cancer; 2023 Dec; 21(6):660-668.e1. PubMed ID: 37858374
[TBL] [Abstract][Full Text] [Related]
57. Prospects for targeting PD-1 and PD-L1 in various tumor types.
Kim JW; Eder JP
Oncology (Williston Park); 2014 Nov; 28 Suppl 3():15-28. PubMed ID: 25387682
[TBL] [Abstract][Full Text] [Related]
58. Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study.
Troeltzsch M; Woodlock T; Pianka A; Otto S; Troeltzsch M; Ehrenfeld M; Knösel T
J Oral Maxillofac Surg; 2017 May; 75(5):969-977. PubMed ID: 27916470
[TBL] [Abstract][Full Text] [Related]
59. Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.
Kwak C; Park YH; Jeong CW; Jeong H; Lee SE; Moon KC; Ku JH
J Surg Oncol; 2007 Mar; 95(4):317-23. PubMed ID: 17066434
[TBL] [Abstract][Full Text] [Related]
60. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]